INS and metabolic syndrome: Indeed, inhibition of hepatic aPKC by liver‐selective agents is accompanied by improvements in insulin‐stimulated activation of IRS‐1/PI3K, Akt, and aPKC in skeletal muscle in various mouse models of DIO/MetS/T2DM.17, 20, 21